MA40865B1 - Thiazoles à substitution amide utilisés comme modulateurs de rorgammat - Google Patents

Thiazoles à substitution amide utilisés comme modulateurs de rorgammat

Info

Publication number
MA40865B1
MA40865B1 MA40865A MA40865A MA40865B1 MA 40865 B1 MA40865 B1 MA 40865B1 MA 40865 A MA40865 A MA 40865A MA 40865 A MA40865 A MA 40865A MA 40865 B1 MA40865 B1 MA 40865B1
Authority
MA
Morocco
Prior art keywords
rorgammat
modulators
amide
substituted thiazoles
compound
Prior art date
Application number
MA40865A
Other languages
English (en)
Inventor
Christoph Steeneck
Christian Gege
Olaf Kinzel
Gerald Kleymann
Thomas Hoffmann
Steven Goldberg
Xiaohua Xue
Hariharan Venkatesan
Virginia Tanis
Maud Urbanski
Aihua Wang
David Kummer
Anne M Fourie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40865B1 publication Critical patent/MA40865B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne des composés de formule i, dans laquelle r1, r2, r3, r5, a1, a2 et ? Sont tels que définis dans la description. L'invention concerne également un composé de formule i destiné à être utilisé dans un procédé pour traiter ou atténuer un syndrome, un trouble ou une maladie, ledit syndrome, ledit trouble ou ladite maladie étant la polyarthrite rhumatoïde ou le psoriasis. L'invention concerne également un composé destiné à être utilisé dans un procédé pour moduler l'activité de ror?T chez un mammifère par administration d'une quantité thérapeutiquement efficace d'au moins un composé de la revendication 1.
MA40865A 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorgammat MA40865B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072599P 2014-10-30 2014-10-30
PCT/US2015/058200 WO2016069978A1 (fr) 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorγt

Publications (1)

Publication Number Publication Date
MA40865B1 true MA40865B1 (fr) 2019-11-29

Family

ID=54542554

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40865A MA40865B1 (fr) 2014-10-30 2015-10-30 Thiazoles à substitution amide utilisés comme modulateurs de rorgammat

Country Status (21)

Country Link
US (1) US9845319B2 (fr)
EP (1) EP3212642B1 (fr)
JP (1) JP6695335B2 (fr)
KR (1) KR20170075787A (fr)
CN (1) CN108064224B (fr)
AU (1) AU2015339091B2 (fr)
BR (1) BR112017008852A2 (fr)
CA (1) CA2965518A1 (fr)
CY (1) CY1122563T1 (fr)
DK (1) DK3212642T3 (fr)
ES (1) ES2767303T3 (fr)
HR (1) HRP20200016T1 (fr)
HU (1) HUE046888T2 (fr)
IL (1) IL251857B (fr)
MA (1) MA40865B1 (fr)
PL (1) PL3212642T3 (fr)
PT (1) PT3212642T (fr)
RS (1) RS59752B1 (fr)
SI (1) SI3212642T1 (fr)
SM (1) SMT201900706T1 (fr)
WO (1) WO2016069978A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3212641T (lt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazolai, kaip roryt moduliatoriai
TWI667230B (zh) 2014-10-30 2019-08-01 比利時商健生藥品公司 用作ＲＯＲγｔ調節劑之三氟甲基醇
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
EP3765009A4 (fr) * 2018-03-12 2021-11-10 Escalier Biosciences, BV Modulateurs de ror-gamma bicycliques
BR112020018718A2 (pt) 2018-03-12 2021-03-09 Escalier Biosciences B.V. Moduladores de ror-gama espirocíclicos
CA3103929A1 (fr) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazoles substitues par phenyle utilises en tant que modulateurs de roryt
EP3806958B1 (fr) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles en tant que modulateurs de roryt
EA202092962A1 (ru) * 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
WO1996003392A1 (fr) 1994-07-27 1996-02-08 G.D. Searle & Co. Thiazoles substitues destines au traitement de l'inflammation
CN100540538C (zh) 2001-04-16 2009-09-16 田边三菱制药株式会社 高传导率钙-活化k通道开启剂
WO2003015776A1 (fr) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Derives de thiazolyl 2,4,5-trisubstitue et activite anti-inflammatoire associee
US20050014805A1 (en) * 2001-10-12 2005-01-20 Chenzhi Zhang Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
TWI444370B (zh) 2006-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於發炎及免疫相關用途之噻唑及噻二唑化合物
WO2008064318A2 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes périphériques
WO2008064317A1 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes lipophiles
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0916218B1 (pt) 2008-07-17 2018-11-27 Bayer Cropscience Ag compostos heterocíclicos como composições praguicidas
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
ES2703176T3 (es) 2010-03-11 2019-03-07 Univ New York Compuestos amido como moduladores de RORgammat y usos de los mismos
WO2011115892A1 (fr) 2010-03-15 2011-09-22 Griffin Patrick R Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
WO2012027965A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
WO2012074547A2 (fr) 2010-11-29 2012-06-07 New York University COMPOSÉS STÉROÏDES COMME MODULATEURS DE RORγT ET LEURS UTILISATIONS
EP2660597B1 (fr) 2010-12-28 2017-09-13 ARKRAY, Inc. Procédé pour évaluer l'état d'une cavité buccale, et dispositif, appareil et programme d'analyse associés
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
WO2012158784A2 (fr) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulateurs des récepteurs orphelins apparentés aux récepteurs hormonaux nucléaires
WO2013018695A1 (fr) 2011-07-29 2013-02-07 武田薬品工業株式会社 Composé hétérocyclique
HK1199839A1 (en) 2011-09-09 2015-07-24 New York University Amido compounds as ror-gamma-tmodulators and uses thereof
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
NZ702539A (en) 2012-05-31 2016-11-25 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
WO2015035278A1 (fr) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company Modulateurs de rorγ
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
EP3046906B1 (fr) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Modulateurs de ror gamma
AU2014359324B2 (en) 2013-12-05 2019-02-21 Lead Pharma Holding B.V. ROR gamma (RORy) modulators
CA2936116A1 (fr) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Derives de pyrrolidinyle sulfone et leur utilisation en tant que modulateurs de ror gamma
US9771320B2 (en) 2014-01-06 2017-09-26 Bristol-Myers Squibb Company Carbocyclic sulfone RORγ modulators
EP3092221B1 (fr) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Sulfones hétérocycliques utilisés en tant que modulateurs de ror gamma
EP3092215B1 (fr) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Composés cyclohéxyle sulfone servant de modulateurs de ror gamma
WO2015145371A1 (fr) 2014-03-27 2015-10-01 Piramal Enterprises Limited Modulateurs de ror-gamma et leurs utilisations
CN103833672A (zh) * 2014-03-28 2014-06-04 中国药科大学 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法

Also Published As

Publication number Publication date
RS59752B1 (sr) 2020-02-28
BR112017008852A2 (pt) 2018-01-16
KR20170075787A (ko) 2017-07-03
CA2965518A1 (fr) 2016-05-06
CN108064224B (zh) 2022-03-29
US20160122335A1 (en) 2016-05-05
IL251857B (en) 2020-09-30
WO2016069978A1 (fr) 2016-05-06
HRP20200016T1 (hr) 2020-03-20
EP3212642A1 (fr) 2017-09-06
JP6695335B2 (ja) 2020-05-20
DK3212642T3 (da) 2019-11-25
EP3212642B1 (fr) 2019-10-30
CY1122563T1 (el) 2021-01-27
PT3212642T (pt) 2019-12-19
HUE046888T2 (hu) 2020-03-30
JP2018500286A (ja) 2018-01-11
SI3212642T1 (sl) 2020-01-31
ES2767303T3 (es) 2020-06-17
SMT201900706T1 (it) 2020-01-14
AU2015339091B2 (en) 2020-05-28
CN108064224A (zh) 2018-05-22
US9845319B2 (en) 2017-12-19
HK1243418A1 (en) 2018-07-13
IL251857A0 (en) 2017-06-29
AU2015339091A1 (en) 2017-05-11
PL3212642T3 (pl) 2020-04-30

Similar Documents

Publication Publication Date Title
MA40863B1 (fr) Thiazoles en tant que modulateurs de roryt
MA40873A (fr) Alcools trifluorométhylés utilisés comme modulateurs de roryt
MA64510B1 (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA40290A1 (fr) Agents immunorégulateurs
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
EA202191519A1 (ru) Модуляторы trex1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
EA201991898A1 (ru) Двойные ингибиторы magl и faah
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201892438A1 (ru) 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
MX2020011489A (es) Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina.
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA202190452A1 (ru) Ингибиторы cdk8/19
MY199104A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
MA54518B1 (fr) 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs